These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 34099985)

  • 1. In silico molecular docking analysis for repurposing approved antiviral drugs against SARS-CoV-2 main protease.
    Khater I; Nassar A
    Biochem Biophys Rep; 2021 Sep; 27():101032. PubMed ID: 34099985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the Binding Affinity of Anti-Viral Drugs against Main Protease of SARS-CoV-2 Through a Molecular Docking Study.
    Mondal M; Sarkar C; Jamaddar S; Khalipha ABR; Islam MT; Mahafzah A; Mubarak MS
    Infect Disord Drug Targets; 2021; 21(7):e160921188777. PubMed ID: 33292147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug repurposing studies targeting SARS-CoV-2: an ensemble docking approach on drug target 3C-like protease (3CL
    Koulgi S; Jani V; Uppuladinne M; Sonavane U; Nath AK; Darbari H; Joshi R
    J Biomol Struct Dyn; 2021 Sep; 39(15):5735-5755. PubMed ID: 32679006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
    Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
    Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The inhibitory effect of some natural bioactive compounds against SARS-CoV-2 main protease: insights from molecular docking analysis and molecular dynamic simulation.
    Abdelrheem DA; Ahmed SA; Abd El-Mageed HR; Mohamed HS; Rahman AA; Elsayed KNM; Ahmed SA
    J Environ Sci Health A Tox Hazard Subst Environ Eng; 2020; 55(11):1373-1386. PubMed ID: 32998618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19.
    Talluri S
    Comb Chem High Throughput Screen; 2021; 24(5):716-728. PubMed ID: 32798373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19.
    Rai H; Barik A; Singh YP; Suresh A; Singh L; Singh G; Nayak UY; Dubey VK; Modi G
    Mol Divers; 2021 Aug; 25(3):1905-1927. PubMed ID: 33582935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2.
    Deshpande RR; Tiwari AP; Nyayanit N; Modak M
    Eur J Pharmacol; 2020 Nov; 886():173430. PubMed ID: 32758569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential anti-viral activity of approved repurposed drug against main protease of SARS-CoV-2: an
    Mahanta S; Chowdhury P; Gogoi N; Goswami N; Borah D; Kumar R; Chetia D; Borah P; Buragohain AK; Gogoi B
    J Biomol Struct Dyn; 2021 Jul; 39(10):3802-3811. PubMed ID: 32406317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug repurposing of FDA-approved anti-viral drugs via computational screening against novel 6M03 SARS-COVID-19.
    Waseem W; Zafar R; Jan MS; Alomar TS; Almasoud N; Rauf A; Khattak H
    Ir J Med Sci; 2024 Feb; 193(1):73-83. PubMed ID: 37515684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repurposing of known anti-virals as potential inhibitors for SARS-CoV-2 main protease using molecular docking analysis.
    Hakmi M; Bouricha EM; Kandoussi I; Harti JE; Ibrahimi A
    Bioinformation; 2020; 16(4):301-306. PubMed ID: 32773989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
    Indu P; Rameshkumar MR; Arunagirinathan N; Al-Dhabi NA; Valan Arasu M; Ignacimuthu S
    J Infect Public Health; 2020 Dec; 13(12):1856-1861. PubMed ID: 33168456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing a SARS-CoV-2 main protease binding prediction random forest model for drug repurposing for COVID-19 treatment.
    Liu J; Xu L; Guo W; Li Z; Khan MKH; Ge W; Patterson TA; Hong H
    Exp Biol Med (Maywood); 2023 Nov; 248(21):1927-1936. PubMed ID: 37997891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-HCV and anti-malaria agent, potential candidates to repurpose for coronavirus infection: Virtual screening, molecular docking, and molecular dynamics simulation study.
    Hosseini FS; Amanlou M
    Life Sci; 2020 Oct; 258():118205. PubMed ID: 32777300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular docking and dynamic simulations for antiviral compounds against SARS-CoV-2: A computational study.
    Peele KA; Potla Durthi C; Srihansa T; Krupanidhi S; Ayyagari VS; Babu DJ; Indira M; Reddy AR; Venkateswarulu TC
    Inform Med Unlocked; 2020; 19():100345. PubMed ID: 32395606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease.
    Fadaka AO; Sibuyi NRS; Martin DR; Klein A; Madiehe A; Meyer M
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of Iminosugars as Antiviral Agents against SARS-CoV-2 Main Protease: Inhibitor Design and Optimization, Molecular Docking, and Molecular Dynamics Studies to Explore Potential Inhibitory Effect of 1-Deoxynojirmycin Series.
    Miglani V; Sharma P; Kumar Narula A
    Curr Comput Aided Drug Des; 2023 Aug; ():. PubMed ID: 37612857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.